Stefanos Zenios Professor of Disruptive Innovation Stanford University
David Coman CEO Science 37
Jennifer Buechel Chief Operating Officer Delfi Diagnostics
Jacob LaPorte Co-Founder & Global Head, BIOME Novartis
Paul Simms Chief Executive Impatient Health
When those of us working in clinical trials hear the phrase ‘disruptive innovation’, we’re pulled in opposite directions. We’re excited about something new, addressing the huge unfulfilled potential—exploring the impact and potential on research and patient experience. But we’re also inhibited, aware of the barriers and sensitivities ahead—with regulators and patients as critical customers that must be managed, and scientific rigor to uphold.
Across industries, leaders examine disruptive innovation, looking at the inflection points that lead to broader adoption. The adoption phase in decentralization is now. Yes, there has been inhibition and concern over regulatory acceptance, but the transformative benefits cannot be ignored.
Join us for a masterclass conversation with leaders and innovators from Stanford and Science 37, as we discuss decentralization from a disruption standpoint—looking to uncover where we are in terms of adoption. Learn more about agile technologies and industry standards that are needed to drive clinical trial innovation, as we move towards universal adoption of decentralization.